

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Stockholm, Sweden

22 March 2017

ABG Sundal Collier AB ("ABGSC") has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company's shares have been effected.

As previously announced, ABGSC is acting as stabilisation manager in connection with the offer to acquire shares in the Company and the listing on Nasdaq Stockholm (the "Offering"), and ABGSC may, acting as a stabilisation manager, effect transactions aimed at supporting the market price of the shares at levels above those which might otherwise prevail in the open market.

Such stabilisation transactions may be effected on Nasdaq Stockholm, the OTC market, or otherwise, at any time during the period starting on the date of commencement of trading in the shares on Nasdaq Stockholm and ending no later than 30 calendar days thereafter. ABGSC is, however, not required to undertake any stabilisation, and there is no assurance that stabilisation will be undertaken. Stabilisation, if undertaken, may furthermore be discontinued at any time without prior notice. In no event will transactions be effected to support the market price of the shares at levels above the price in the Offering.

In order to cover potential over-allotment in relation to the Offering, the Company has, at the request of the Joint Global Coordinators (ABGSC and Carnegie Investment Bank AB) committed to issue up to 2,119,565 additional new shares, corresponding to a maximum of 15 percent of the number of shares in the Offering at a price corresponding to the price in the Offering.

ABGSC has announced that ABGSC (contact: Carl Rosenius, tel: +46 8 566 286 85), has performed stabilisation (in accordance with Article 3.2(d) of the EU Market Abuse Regulation) on Nasdaq Stockholm in accordance with what is set out below.

| Stabilisation information: | |
|-----------------------------------|------------------------|
| Issuer: | Oncopeptides AB (publ) |
| Securities: | Shares (SE0009414576) |
| Offering size: | 14,130,434 |
| Offering price: | 46 SEK |
| Ticker: | ONCO |
| Stabilisation manager: | ABG Sundal Collier AB |

| Stabilisation transactions: | | | | | | |
|------------------------------------|----------|-----------------|----------------|--------------------------|----------|------------------|
| Date | Quantity | Price (highest) | Price (lowest) | Price (weighted average) | Currency | Market place |
| 2017-03-14 | 12,694 | 44.3 | 43.8 | 44.0313 | SEK | Nasdaq Stockholm |
| 2017-03-15 | 6,111 | 44 | 43.8 | 43.9637 | SEK | Nasdaq Stockholm |
| 2017-03-16 | 11,436 | 44 | 43.8 | 43.9079 | SEK | Nasdaq Stockholm |
| 2017-03-17 | 9,000 | 44 | 43.9 | 43.94444 | SEK | Nasdaq Stockholm |
| 2017-03-20 | 16,000 | 43.5 | 43.4 | 43.4375 | SEK | Nasdaq Stockholm |
| 2017-03-21 | 51,226 | 43.3 | 42.5 | 42.8961 | SEK | Nasdaq Stockholm |
| 2017-03-22 | 28,553 | 42.4 | 41.3 | 41.7956 | SEK | Nasdaq Stockholm |

For further information, please contact:

Jakob Lindberg, CEO at Oncopeptides

E-mail: jakob.lindberg@oncopeptides.se

Rein Piir, Head of Investor Relations at Oncopeptides

E-mail: rein.piir@oncopeptides.se

This information is such that Oncopeptides is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on March 22, 2017 at 7.30 p.m (CET).

About Oncopeptides

Oncopeptides is a research and development stage pharmaceutical company developing drugs for treatment of cancer. Since the founding of the Company in 2000, the Company has focused primarily on the development of the product candidate Ygalo, an innovative peptidase-potentiated alkylator intended for effective and focused treatment of blood-based cancer diseases, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide treating physicians with a new treatment option for patients suffering from this severe cancer disease.

Important information

This announcement is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, the United Kingdom, Canada, Australia, South Africa, Japan or any other state or jurisdiction in which release, publication or distribution would be unlawful.

This announcement is not an offer of securities for sale in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Oncopeptides AB does not intend to register any of the securities in the United States or to conduct a public offering of the securities in the United States.

This communication does not constitute an offer of the securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the securities. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.

Matters discussed in this communication may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialise or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this presentation are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or any obligation to update or revise the statements in this presentation to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this document.

The information, opinions and forward-looking statements contained in this communication speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.